Comparative efficacy of golimumab, infliximab, and adalimumab for moderately to severely active ulcerative colitis: a network meta-analysis accounting for differences in trial designs-Reference-Cited by-同舟云学术

Comparative efficacy of golimumab, infliximab, and adalimumab for moderately to severely active ulcerative colitis: a network meta-analysis accounting for differences in trial designs

Published:2015-03-12 Issue:5 Volume:9 Page:693-700
ISSN:1747-4124
Container-title:Expert Review of Gastroenterology & Hepatology
language:en
Short-container-title:Expert Review of Gastroenterology & Hepatology

Author:

Thorlund Kristian,Druyts Eric,Toor Kabirraaj,Mills Edward J

Publisher

Informa UK Limited

Subject

Gastroenterology,Hepatology

Link

http://www.tandfonline.com/doi/pdf/10.1586/17474124.2015.1024657

Reference15 articles.

1. Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial

2. Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis

3. Subcutaneous Golimumab Induces Clinical Response and Remission in Patients With Moderate-to-Severe Ulcerative Colitis

4. Subcutaneous Golimumab Maintains Clinical Response in Patients With Moderate-to-Severe Ulcerative Colitis

5. Adalimumab Induces and Maintains Clinical Remission in Patients With Moderate-to-Severe Ulcerative Colitis

Cited by 51 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and safety of infliximab and adalimumab in inflammatory bowel disease patients;Inflammopharmacology;2024-07-10

2. Maintenance of clinical remission with biologics and small molecules in inflammatory bowel disease according to trial design: Meta-analysis;Digestive and Liver Disease;2024-01

3. Clinical and treatment outcomes of a second subcutaneous or intravenous anti-TNF in patients with ulcerative colitis treated with two consecutive anti-TNF agents: data from the ENEIDA registry;Therapeutic Advances in Gastroenterology;2024-01

4. Network meta-analysis on efficacy and safety of different biologics for ulcerative colitis;BMC Gastroenterology;2023-10-06

5. Real-World Persistency for Inflammatory Bowel Disease Biologics Using Patient Registry Data;Crohn's & Colitis 360;2023-09-18